<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14</volume><submitter>Duijster JW</submitter><funding>Ministerie van Volksgezondheid, Welzijn en Sport</funding><pubmed_abstract>&lt;h4>Background&lt;/h4>Albeit the need for sex-disaggregated results of adverse events after immunization (AEFIs) is gaining attention since the COVID-19 pandemic, studies with emphasis on sexual dimorphism in response to COVID-19 vaccination are relatively scarce. This prospective cohort study aimed to assess differences in the incidence and course of reported AEFIs after COVID-19 vaccination between males and females in the Netherlands and provides a summary of sex-disaggregated outcomes in published literature.&lt;h4>Methods&lt;/h4>Patient reported outcomes of AEFIs over a six month period following the first vaccination with BioNTech-Pfizer, AstraZeneca, Moderna or the Johnson&amp;Johnson vaccine were collected in a Cohort Event Monitoring study. Logistic regression was used to assess differences in</pubmed_abstract><journal>Frontiers in immunology</journal><pagination>1078736</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9922710</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature.</pubmed_title><pmcid>PMC9922710</pmcid><pubmed_authors>Raethke M</pubmed_authors><pubmed_authors>Pacelli S</pubmed_authors><pubmed_authors>Van Hunsel F</pubmed_authors><pubmed_authors>Van Balveren L</pubmed_authors><pubmed_authors>Ruijs LS</pubmed_authors><pubmed_authors>Kant A</pubmed_authors><pubmed_authors>Duijster JW</pubmed_authors><pubmed_authors>Lieber T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature.</name><description>&lt;h4>Background&lt;/h4>Albeit the need for sex-disaggregated results of adverse events after immunization (AEFIs) is gaining attention since the COVID-19 pandemic, studies with emphasis on sexual dimorphism in response to COVID-19 vaccination are relatively scarce. This prospective cohort study aimed to assess differences in the incidence and course of reported AEFIs after COVID-19 vaccination between males and females in the Netherlands and provides a summary of sex-disaggregated outcomes in published literature.&lt;h4>Methods&lt;/h4>Patient reported outcomes of AEFIs over a six month period following the first vaccination with BioNTech-Pfizer, AstraZeneca, Moderna or the Johnson&amp;Johnson vaccine were collected in a Cohort Event Monitoring study. Logistic regression was used to assess differences in</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023</publication><modification>2026-03-17T15:56:25.202Z</modification><creation>2025-04-04T11:16:40.554Z</creation></dates><accession>S-EPMC9922710</accession><cross_references><pubmed>36793715</pubmed><doi>10.3389/fimmu.2023.1078736</doi></cross_references></HashMap>